203 related articles for article (PubMed ID: 34788758)
1. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.
Forrer F; Fischer GF; Maas O; Giovanella L; Hoffmann M; Iakovou I; Luster M; Mihailovic J; Petranovic Ovčariček P; Vrachimis A; Zerdoud S; Putora PM
Oncology; 2022; 100(2):74-81. PubMed ID: 34788758
[TBL] [Abstract][Full Text] [Related]
2. Variations in radioiodine ablation: decision-making after total thyroidectomy.
Maas O; Forrer F; Maas M; Panje CM; Blautzik J; Brühlmeier M; Engel-Bicik I; Giovanella L; Haldemann A; Kamel ME; Kneifel S; Rottenburger C; Schaefer N; Walter MA; Weidner S; Putora PM
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):554-560. PubMed ID: 31707428
[TBL] [Abstract][Full Text] [Related]
3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
4. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
[TBL] [Abstract][Full Text] [Related]
6. Controversies, Consensus, and Collaboration in the Use of
Tuttle RM; Ahuja S; Avram AM; Bernet VJ; Bourguet P; Daniels GH; Dillehay G; Draganescu C; Flux G; Führer D; Giovanella L; Greenspan B; Luster M; Muylle K; Smit JWA; Van Nostrand D; Verburg FA; Hegedüs L
Thyroid; 2019 Apr; 29(4):461-470. PubMed ID: 30900516
[TBL] [Abstract][Full Text] [Related]
7. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
[TBL] [Abstract][Full Text] [Related]
8. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.
Luster M; Aktolun C; Amendoeira I; Barczyński M; Bible KC; Duntas LH; Elisei R; Handkiewicz-Junak D; Hoffmann M; Jarząb B; Leenhardt L; Musholt TJ; Newbold K; Nixon IJ; Smit J; Sobrinho-Simões M; Sosa JA; Tuttle RM; Verburg FA; Wartofsky L; Führer D
Thyroid; 2019 Jan; 29(1):7-26. PubMed ID: 30484394
[TBL] [Abstract][Full Text] [Related]
9. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature.
Estorch M; Mitjavila M; Muros MA; Caballero E;
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(3):195-203. PubMed ID: 30745131
[TBL] [Abstract][Full Text] [Related]
11. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
[TBL] [Abstract][Full Text] [Related]
14. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
15. Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.
Schmidt M; Bartenstein P; Bucerius J; Dietlein M; Drzezga A; Herrmann K; Lapa C; Lorenz K; Musholt TJ; Nagarajah J; Reiners C; Sahlmann CO; Kreissl MC
Nuklearmedizin; 2022 Apr; 61(2):87-96. PubMed ID: 35299276
[TBL] [Abstract][Full Text] [Related]
16. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
Bal CS; Kumar A; Pant GS
Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
[TBL] [Abstract][Full Text] [Related]
19. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
Mazzaferri EL; Kloos RT
Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
[TBL] [Abstract][Full Text] [Related]
20. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines.
Albano D; Bertagna F; Bonacina M; Durmo R; Cerudelli E; Gazzilli M; Panarotto MB; Formenti AM; Mazziotti G; Giustina A; Giubbini R
Eur J Endocrinol; 2018 Sep; 179(3):143-151. PubMed ID: 29899030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]